A carregar...
First report on a prospective trial with yttrium-90–labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma
Most patients with primary CNS lymphoma (PCNSL) relapse after primary therapy. Standard salvage treatment has not yet been established in PCNSL. Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood–brain barrie...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Duke University Press
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2743222/ https://ncbi.nlm.nih.gov/pubmed/19060176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2008-108 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|